Drugs / BANOXANTRONE
BANOXANTRONE
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00090727 | Aug 2004 → ? | cancer, non-Hodgkin lymphoma | Novacea | Unknown | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT00394628 | Oct 2006 → ? | glioblastoma | Novacea | Unknown | No outcome recorded |
| Phase 1/2 | NCT00109356 | Mar 2005 → Mar 2007 | chronic lymphocytic leukemia/small lymphocytic lymphoma | Novacea | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BANOXANTRONE | ChEMBL registry synonym — accepted as the source's own label CHEMBL117391 ↗ |
| Known as | AQ4N | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00394628 ↗ |
| Known as | Banoxantrona | ChEMBL registry synonym — accepted as the source's own label CHEMBL117391 ↗ |
| Modality | Small molecule | — CHEMBL117391 ↗ |
| Route | Intravenous | “AQ4N Administered Intravenously” NCT00090727 ↗ |